XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
In-process research and development impairment $ 2,700 $ 0 $ 0
Fair value | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short-term and long-term debt 21,900 28,600  
Fair value | Level 3 | Immunomedics, Inc. | Fair Value, Nonrecurring      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Future royalties 1,100 1,300  
Carrying value | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short-term and long-term debt 24,100 25,600  
Carrying value | Level 3 | Immunomedics, Inc. | Fair Value, Nonrecurring      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Future royalties $ 1,100 $ 1,100